**Abstract:** Invasive aspergillosis (IA) has poor prognosis in immunocompromised patients. Skin manifestations, when present, should contribute to an early diagnosis. The authors aimed to provide prevalence data and a clinical and histologic description of cutaneous manifestations of primary cutaneous IA (PCIA) and secondary CIA (SCIA) in a unique clinical series of IA and present the results of an exhaustive literature review of CIA. Cases of proven and probable IA were included. Among the 1,410 patients with proven or probable IA, 15 had CIA (1.06%), 5 PCIA, and 10 SCIA. Hematological malignancies were the main underlying condition (12/15). Patients with CIA presented infiltrated and/or suppurative lesions of various localizations not related to a catheter site (4/5), whereas SCIA was mainly characterized by disseminated papules and nodules but sometimes isolated nodules or cellulitis. Histologic data were available for 11 patients, and for 9, similar for PCIA and SCIA, showed a dense dermal polymorphic inflammatory infiltrate, with the epidermis altered. Any periodical acid Schiff and Gomori-Grocott methenamine silver nitrate staining for all but 2 biopsies revealed hyphal compatible with *Aspergillus*. *Aspergillus flavus* was isolated in all cases of PCIA, with *Aspergillus fumigatus* being the most frequent species (6/10) in SCIA. Two out of 5 PCIA cases were treated surgically. The 3-month survival rate was 100% and 30% for PCIA and SCIA, respectively. Our study is the largest adult series of CIA and provides complete clinical and histologic data for the disease. Primary cutaneous IA should be recognized early, and cases of extensive necrosis should be treated surgically; its prognosis markedly differs from that for SCIA. Any suppurative, necrotic, papulonodular, or infiltrated skin lesion in an immunocompromised patient should prompt prompt consideration of IA.

**DOI:** 10.1097/MD.0000000000001018

**Conflict of interest:** O.L. is consultant for Gilead Sciences, has received speaking honoraria from Pfizer and Gilead Sciences and travel grants from Astellas and Pfizer. S.B. is consultant for Gilead Sciences, has received speaking honoraria from Pfizer and Gilead Sciences and travel grants from Astellas and Pfizer.

**Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.**
immunocompromised patient should lead to immediate biopsy for histologic analysis and mycological skin direct examination and culture.

(ABSTRACT: CIA = cutaneous invasive aspergillosis, EORTC/MSG = European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group, HES = hematoxylin–eosin–safron, IA = invasive aspergillosis, NRCPMA = National Reference Center for Invasive Mycoses and Antifungals, PAS = Periodic acid Schiff, PCIA = primary cutaneous invasive aspergillosis, SAIF = Surveillance des Aspergilloses Invasives en France, SCIA = secondary cutaneous invasive aspergillosis.}

INTRODUCTION

Invasive aspergillosis (IA) is an opportunistic fungal infection caused by Aspergillus spp. in immunocompromised patients, usually after inhalation of spores. Invasive aspergillosis has been defined by the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) and classified in 3 levels of probability: proven aspergillosis defined by histologic evidence of compatible hyphae and isolation of the fungus by culture from a normally sterile site; probable aspergillosis defined by the association of host (risk) factors together with clinical and mycological (direct or indirect test) criteria; and possible aspergillosis defined by the combination of clinical evidence and appropriate host factors without mycological support. The mortality rate of IA has been reported to be between 35% and 55% at 12 weeks in immunocompromised patients. Early diagnosis, however, can improve survival. Risk factors, diagnostic tools, prognostic factors, and treatment have been reviewed, with consensus. Little is known about cutaneous manifestations of IA because of the unknown prevalence of the involvement and the limited number of dedicated series.

Cutaneous invasive aspergillosis (CIA) is commonly divided into primary and secondary lesions, primarily accounting for necrotic lesions that result from direct inoculation of the fungus at the injury site and secondary lesions resulting from the blood spreading of hyphae. Cutaneous invasive aspergillosis is commonly described as presenting with more or less pruritic papules, nodules, or plaques with secondary escharotic evolution. Despite several adult case reports and pediatric series, few large series of CIA, however, have been published, and the clinical and histologic spectrum of the disease remain underestimated.

Therefore, we performed a retrospective analysis of proven and probable cases of IA with cutaneous manifestations collected in France between 2005 and 2010 by an active surveillance network. We aimed to: provide data on the prevalence of cutaneous manifestations with primary CIA (PCIA) and secondary CIA (SCIA) in a unique clinical series, give a clinical and histologic description of CIA, and present the results of an exhaustive literature review of CIA.

METHODS

Data Source

The prospective active Surveillance des Aspergilloses Invasives en France (SAIF) network is a French anonymous centralized database (National Reference Center for Invasive Mycoses and Antifungals, Institut Pasteur, Paris) relying on voluntary (as the declaration of IA cases is not mandatory) but systematic declaration of IA by mycologists from predefined university hospitals in France. On the standardized anonymous declaration, a web-based file, practitioners had to systematically mention the presence of skin involvement. All records with cutaneous involvement for January 2005 to July 2010 were extracted and analyzed.

Selection of Patients

Proven and probable cases of IA were retained according to the EORTC/MSG definition criteria (criteria published in 2002 for the period 2005–2007 and published in 2008 for 2008–2010). We first extracted from the database all cases with notified cutaneous involvement. Then, we systematically reviewed patient charts. We included patients with cutaneous lesions in accordance with previously published lesions suggestive of cutaneous aspergillosis or infectious dermatitis (ie, papules, nodules, necrosis, pustules, ulcerations, and/or suppuration), then classified patients as having proven or probable CIA as follows:

1. Proven CIA was defined by a skin biopsy showing histologic evidence of compatible hyphae and/or positive mycological culture of the skin biopsy.
2. Probable CIA was considered in patients with proven or probable IA and skin involvement clinically compatible with an infectious origin but no histologic features of fungal infection and no positive skin culture biopsy. To consider these patients as having probable CIA, a positive cutaneous mycological sample taken by swab, however, was needed.

The following data were recorded from files for patients with proven or probable CIA: age, sex, underlying disease, clinical features and localization of cutaneous lesions, time between cutaneous lesion appearance and the skin biopsy, fungal identification, treatment, and 3-month survival. Skin biopsies were retrospectively reviewed by a dermatopathologist of our team (NO) with blinding to the type of CIA (primary or secondary).

Two groups of patients were defined: those with PCIA (ie, presenting a unique skin lesion and no visceral involvement) and those with SCIA, characterized by the association of skin and visceral involvement or the presence of multiple cutaneous lesions (in 2 or more noncontiguous areas) suggestive of disseminated disease even in the absence of organ involvement.

The research complied with French law and the Declaration of Helsinki (as adopted in 2000), and was approved by the local institutional research board committee (CPP-H de France IX). Approval of the Commission Nationale de l’Informatique et des Libertés (CNIL) was obtained, ensuring that patient data were kept anonymous according to French regulations.

Literature Review Search Strategy

We search MEDLINE via PubMed for articles published from January 1985 to July 2014 by using the key words “skin”, “cutaneous”, and “invasive aspergillosis”. The literature search yielded 720 citations. From these, we included only English language studies of skin involvement with IA and including more than 3 patients. This research was completed by an analysis of reviews of cutaneous invasion for the purpose of the discussion.
RESULTS

Collection of Data

In total, 1410 cases of proven or probable IA were registered in the SAIF database, and 21 had cutaneous involvement noted (Figure 1). Six patients were excluded after systematic analysis of corresponding medical charts [cutaneous manifestations not consistent with cutaneous infection (drug reaction), N = 4; unavailable chart, N = 1; no histologic or mycological criteria, N = 1]. We included 15 patients, allowing to estimate to 1.06% the prevalence of skin lesions in proven or probable IA. According to our definitions, 13 patients presented proven CIA (skin histology findings, N = 9; positive mycological culture of skin biopsy, N = 13) and 2 probable CIA (positive swab culture). Five patients had PCIA and 10 had SCIA.

Patient Characteristics

Epidemiological Data and General Conditions

The median age of patients was 56 years (range 1–90) and 9 (60%) were men; 12 (80%) had an underlying hematological malignancy and 4 (26%) a solid organ transplant (2 liver transplant, including a patient also with hematological malignancy, 1 heart, and 1 kidney transplant).

Visceral involvement in SCIA included the central nervous system (2/10), pulmonary (7/10), cardiac (1/10), and sinus (1/10). In 5 patients of PCIA, no systemic involvement was recorded.

Fever defined by temperature >38°C was present in 5/10 SCIA and 5/5 PCIA cases. Septic shock was reported in 2/10 SCIA cases (1 because of Escherichia coli infection and 1 not documented) and 1/5 PCIA cases (not documented). In total, 1/5 patients with PCIA had an intravenous catheter adjacent to the fungal cutaneous lesion. Portal of entry was not found for other patients.

The median time between the appearance of the first cutaneous lesions and skin biopsy was 4 days (range 1–90 days) for SCIA and 5 days (range 0–19 days) for PCIA (Table 1).

Dermatological Findings

In SCIA, lesions were reported as unique or multiple papules or nodules in various localizations (Figure 2A and B). Lesions were described as erythematous, infiltrated, and inflammatory in every patient, and necrosis was observed in 2/10 patients. One patient had a periorbital cellulitis overlying a fungal sinusitis.

In PCIA, lesions presented as paronychia of the big toe in patients 11 and 12, with secondary necrosis and adjacent cellulitis of the leg in patient 11 (Figure 2C); patient 13 presented necrotic infiltrated plaque located next to a catheter insertion site (Figure 2D), patient 14 a necrotic nodule of the calf, and patient 15 swelling of a thoracotomy scar without mediastinitis (Table 1).

Mycological Findings

Mycological examination of cutaneous samples was performed on a skin biopsy in 13 patients and on a swab of purulent material in 2 (probable cases, patients 12 and 15). Aspergillus sp. grew from all skin biopsies of SCIA and represented A. fumigatus (6/10), A. flavus (3/10), and A. nidulans (1/10). Aspergillus flavus was the only species isolated in all PCIA cases. Serum galactomannan assay results were positive in 7/10 SCIA and 3/5 PCIA cases, and negative in other cases (cutoff for positivity 0.5).

Histologic Findings

Histologic examination was performed in 11 patients (8 SCIA and 3 PCIA). In 9 biopsies (6 SCIA and 3 PCIA), the dermis was occupied by a polymorphic inflammatory infiltrate containing altered neutrophils (9/9), lymphocytes (5/9), and histiocytes (8/9) without plasma cells or granuloma formation. Small dermal vessels were often necrotic (Figure 3A). Two other biopsies (SCIA) were not contributive, showing
| Patient no, | Proven or Probable Invasive Aspergillosis | Underlying Disease | Bone Marrow Transplantation | Clinical Presentation | Time From Onset of Lesions and Skin Biopsy or Swelling Culture (Days) | Cutaneous Histologic Aspect (ND) | Fungal Skin Culture (Biopsy or Swab): +, − | Aspergillus spp. | Galactomannan Assay: +, − | Other Organ Involvement | Mode of Diagnosis | Treatment | Outcome at 3 Months |
|------------|------------------------------------------|--------------------|----------------------------|-----------------------|---------------------------------------------------------------|-------------------------------|---------------------------------|-----------------|-------------------|-----------------|-----------------|-----------|----------------------|
| 1, M, 53   | Proven Liver transplantation              | No                 | Multiple inflammatory nodules of the lower limbs | No                    | 60                                                            | Altered neutrophils in the dermis. No hyphae visible in HES. PAS and Grocott staining (+) | +                | A. fumigatus         | −               | No              | Skin culture       | Voriconazole   | A         |
| 2, F, 56   | Proven Chronic lymphocytic leukemia       | Yes, allogenic     | Multiple inflammatory nodules of the lower limbs | No                    | 2                                                             | Altered neutrophils in the dermis. Presence of hyphae in HES. PAS and Grocott staining (+) | +                | A. fumigatus         | +               | No              | Positive serum galactomannan and fever | Amphotericin B  | D         |
| 3, F, 52   | Proven B cell lymphoma and liver transplantation | Yes, allogenic | Unique painful erythematous nodule of the thigh | No                    | 4                                                             | Altered neutrophils and lymphocytes in the dermis. Presence of hyphae in HES. PAS and Grocott staining (+) | +                | A. fumigatus         | +               | Lung            | Skin culture       | Voriconazole caspofungin | D         |
| 4, F, 56   | Proven Kidney transplantation             | No                 | >50 Inflammatory and/or necrotic nodules of the trunk, upper and lower limbs | Yes                   | 90                                                            | Altered neutrophils and lymphocytes in the dermis. Presence of hyphae and targets in HES. PAS and Grocott staining (+) | +                | A. fumigatus         | +               | Endocarditis | Skin culture       | Voriconazole   | D         |
| 5, M, 2    | Proven Acute lymphoblastic leukemia       | No                 | 4 necrotic nodules and 1 pustule of the right upper limb | Yes                   | 1                                                             | Numerous intravascular hyphae | +                | A. flavus           | −               | Lung            | Skin culture       | Voriconazole caspofungin | A         |
| 6, M, 40   | Proven Angioimmunoblastic lymphadenopathy | Yes, allogenic     | >10 inflammatory nodules of the trunk and lower limbs | No                    | 2                                                             | −                            | +                | A. nidulans         | +               | Lung, brain | Positive serum galactomannan and fever | Amphotericin B caspofungin | D         |
| 7, M, 63   | Proven Chronic lymphocytic leukemia       | Yes, allogenic     | Periorbital cellulitis | No                    | 5                                                             | −                            | +                | A. flavus           | +               | Lung, sinus | Skin culture       | Voriconazole   | D         |
| 8, F, 28   | Proven Acute myelogenous leukemia         | No                 | Isolated erythematous nodule of the knee | No                    | No data                                                       | −                            | +                | A. fumigatus         | +               | Lung            | Positive serum galactomannan, bronchoalveolar fluid culture, and fever | Voriconazole A | A         |
| 9, M, 71   | Proven Chronic lymphocytic leukemia       | No                 | Multiple inflammatory nodules of the lower limbs, buttocks, and scalp | No                    | 90                                                            | Altered neutrophils in the dermis. Presence of hyphae in HES. PAS and Grocott staining (+) | +                | A. flavus           | −               | Lung            | Bronchoalveolar fluid culture | Voriconazole A | D         |
| 10, M, 56  | Proven Atypical myeloproliferative syndrome | Yes, allogenic | Multiple inflammatory nodules of the lower limbs | No                    | 1                                                             | −                            | +                | A. fumigatus         | +               | Lung, brain | Skin culture and positive bronchoalveolar fluid culture | Amphotericin B caspofungin | D         |
| Patient no. | Sex, Age | Invasive Disease | Bone Marrow Transplantation | Clinical Presentation | Time From Onset of Lesions and Skin Biopsy or Swelling Culture (Days) | Fungal Skin Culture (Biopsy or Swab), Aspergillus spp., Serum Galactomannan Assay | Other Organ Involvement | Mode of Diagnosis | Treatment | Outcome at 3 Months |
|------------|----------|-----------------|-----------------------------|------------------------|---------------------------------------------------------------|----------------------------------------------------------|--------------------------|-------------------|-----------|---------------------|
| 11, M, 70  | Proven   | Acute myelogenous leukemia | No                          | Yes                    | 4                                                              | + A. flavus                                              | ND                       | +                 | No Skin culture Voriconazole amputation of the big toe | A         |
| 12, M, 57  | Probable | Acute myelogenous leukemia | No                          | No                     | 5 ND                                                             | + A. flavus                                              | No Skin culture Voriconazole | No Swelling culture | A         |
| 13, F, 58  | Proven   | Acute myelogenous leukemia | No                          | Yes                    | 19 ND                                                            | + A. flavus                                              | No Skin culture Voriconazole surgery | No Swelling culture | A         |
| 14, F, 49  | Proven   | Acute lymphogenic leukemia | No                          | Yes                    | 21 ND                                                            | + A. flavus                                              | No Skin culture Amphotericin B caspofungin | No Swelling culture | A         |
| 15, M, 60  | Probable | Heart transplantation | No                          | No                     | 3 ND                                                            | + A. flavus                                              | No Swelling culture Voriconazole | No Swelling culture | A         |

HES, hematoxylin–eosin–safron, ND, not done; PAS, periodic acid Schiff.
nonspecific and mild inflammatory changes in the dermis and no fungal element. The epidermis was normal in SCIA and necrotic in 3/3 PCIA cases. In all 9 informative biopsies, acute septate hyphae were seen within or outside vessels on staining by hematoxylin–eosin–saffron (HES), Gomori-Grocott methenamine silver nitrate (Figure 3B), and periodic acid Schiff (PAS) (Figure 3C), but its detection was easier with Grocott than PAS staining in 3/9 cases. The fungus was visible in the dermis and hypodermis and classified as ramificated (5/9), septate (5/9), short (3/9), or with long hyphae (5/9). Hyphae grouped in clusters were observed in 2 SCIA patients.

Treatment and Follow-up
Antifungal therapy was initiated based on skin culture findings in 6/10 SCIA cases. Treatment for SCIA included voriconazole (5/10), amphotericin B (1/10), voriconazole and caspofungin (2/10), and amphotericin B and caspofungin (2/10). For PCIA, antifungal therapy consisted of voriconazole (4/5) or amphotericin B and caspofungin (1/5) and was associated with surgical detersion of necrosis in 2 patients.

Three months after the diagnosis of CIA, 7/10 SCIA patients (70%) had died, and all patients with PCIA were alive.

Literature Review
Five series of cutaneous IA cases (49 patients; 35 SCIA, 14 PCIA, Table 2) were published as of July 2014. The largest
| First Author (ref) | Year of Publication | Total Number of Patients | Underlying Diseases | Clinical Features | Histologic Features | Species Isolated | Observation |
|-------------------|---------------------|--------------------------|---------------------|-------------------|---------------------|-----------------|-------------|
| Etienne21         | 2011                | 3                        | SCIA                | Extreme prematurity | Patient 1: necrotic rash of the chest, back, and limbs Patient 2: multiple escharotic papules of the back Patient 3: multiple papules of the back | Not described | A. fumigatus (3/3) | All patients were neonates in intensive care unit |
| Burgos11          | 2010                | 16                       | SCIA                | Immunocompromised children (malignancy with or without hematopoietic stem cell transplant) | Not described | Not described | Not specified for skin lesions | Large pediatric retrospective study of 139 cases of IA |
| D’Antonio15       | 2000                | 15                       | (5 PCIA; 10 SCIA)   | Adults (14), child (1) | PCIA: nodular and necrotic lesions (2/5); erythematous infiltration (2/5); erythema next to a catheter site (1/5) SCIA: not described | Not described | PCIA: A. fumigatus (3/5) | 1 PCIA case was presumed from tomography scan |
| Chakrabarti12     | 1998                | 9                        | PCIA                | Adults (9), child (1) | Papulopustular lesion of a finger (1/9), ischorectal abscess (1/9), necrotic ulcer of the cheek (1/9), eschar in burn wound (4/9) Burns (5/9), renal transplant (1/9), postoperative (1/9), none (1/9) | Branching septate hyphae (8/9) | A. flavus (1/5) Aspergillus sp. (1/5) SCIA: A. fumigatus (4/10) A. flavus (5/10) Aspergillus sp. (1/10) A. flavus (5/9), A. fumigatus (1/9), undetermined (1/9) |
| Galimberti13      | 1998                | 6                        | SCIA                | Adults (5), child (1) | Indurated plaque and crust contiguous to sinusitis (3), disseminated nodules or ulcers (3) heart transplant (1), hematological malignancy (3), chronic granulomatous disease (2) | Branched septate hyphae (6) granuloma (4) | A. versicolor (1), A. flavus (2), A. fumigatus (2) |

PCIA, primary cutaneous invasive aspergillosis, SCIA, secondary cutaneous invasive aspergillosis.
series was described in immunocompromised children. In adults, PCIA occurred on skin burns in 5 nonimmunocompromised patients and in immunosuppressed patients in the other cases. A clinical description was available for 9/35 SCIA cases and included necrotic papules, disseminated nodules or papules, or skin induration contiguous to an aspergillosis sinusitis. In total, 7/14 PCIA cases were described as necrotic or escharotic plaques. Histologic features of IA were provided for 18 patients (2 studies) and described as branched septate hyphae (14/18) or granuloma (4/18). A. flavus was predominantly isolated from PCIA patients in 1 series as in our study and A. fumigatus from SCIA patients. Positive serum galactomannan assay findings were not available in most previously published studies. As in our study, the prognosis was better with PCIA than SCIA (53% death rate in Burgos SCIA series).

**DISCUSSION**

The prevalence of cutaneous involvement in IA remained unknown to date. Patterson et al and D’Antonio et al estimated cutaneous involvement at 5% and 4% of IA, respectively, on the basis of retrospective studies. In our series, we could more precisely estimate the prevalence of cutaneous involvement in IA as at least 1% of 1410 cases of proven or probable IA. Most of our patients had an underlying hematological malignancy (80%), which is consistent with other studies. Secondary CIA has been reported in approximately 35 patients, in 2 pediatric series and 3 series of adults. In contrast, reports of PCIA in burn victims and immunocompromised or immunocompetent adults and children are numerous but isolated.

The clinical features of our SCIA patients agreed with the previously reported description of SCIA. Thus, erythematous, disseminated papular, or nodular lesions should be suggestive of CIA in immunocompromised patients with hematological malignancies or solid organ transplantation and should prompt the clinician to immediately take a skin biopsy for histologic examination and mycological microscopy examination and culture. In our series, 2 patients with SCIA had necrotic nodules. Secondary CIA, however, may have a polymorphic presentation such as necrotic lesions or orbital cellulitis, usually more suggestive of mucormycosis and similar to the previously described erythema contiguous to aspergillosis sinusitis, or a unique lesion, which was not previously published and makes the diagnosis of dissemination when skin is the first site evidenced more challenging.

Primary cutaneous IA usually presents as isolated infiltrated lesions. In our series, 1 patient had an infiltrated plaque of the chest and 1 patient a nodule of the calf. We also observed atypical presentations such as 1 case of thoracotomy scar swelling without mediastinitis and 2 patients of necrotic paronychia. Thus, we emphasize the need to evoke CIA with swelling of any localization in patients with hematological malignancy or solid organ transplantation. Furthermore, although predominant in previously published studies, secondary necrosis was observed in only 3/5 PCIA and 2/10 SCIA cases. We did not observe pustules, which are often reported in pediatric cases. A disruption of local skin integrity, often reported as a risk factor for PCIA, was observed in only 1 patient, with a large necrotizing lesion of the chest close to a catheter site. Pathophysiology of PCIA could result from direct inoculation from the environment through a central catheter, on necrotic skin lesions such as burns, or secondary dissemination from onychomycosis caused by Aspergillus infection in immunocompromised patients.

Histologic examination of skin biopsies mainly showed suggestive signs of infection with nonspecific, dermal, and nongranulomatous infiltrates with altered neutrophils and necrosis. We did not observe plasma cells or granuloma formations, in contrast with previous series of SCIA, and no adipocyte necrosis, in contrast with recent findings. The only difference between SCIA and PCIA was the presence of epidermal dystrophy or necrosis in PCIA patients, whereas the epidermis was normal in SCIA. Moreover, the morphologic features of fungal hyphae varied greatly, which could be because of variable times between antifungal treatment initiation and the skin biopsy. In detecting the fungus, sensitivity was higher for PAS and Gomori-Grocott methamine nitrate silver than HES staining.

Fungal culture of a skin biopsy (or swab in 2 patients) allowed early diagnosis when performed in all patients, despite negative histologic findings in 2 patients. Sensitivity was greater for culture than microscopy of the fungus. In our study, biopsy was often delayed after onset of cutaneous symptoms, mostly in secondary forms, which explains why skin involvement allowed for diagnosing IA in 6/10 SCIA cases only. Misdiagnosis of CIA semiology may explain the delay in performing skin biopsy.

Most reported cases of PCIA and SCIA are caused by A. flavus and A. fumigatus, respectively, which agrees with our results. Of note, as was previously reported, only A. flavus was cultured from PCIA samples. Previously published studies showed that A. flavus and A. fumigatus have different pathogenicity pathways and are associated with different clinical presentation. Similarly, the preponderance of A. flavus has been described in the air of some tropical countries, but the country of origin was not captured in the case report form used here.

Positive serum galactomannan assay findings (7/10 SCIA and 3/5 PCIA) were not helpful in discriminating SCIA and PCIA, and positivity in SCIA cases was not associated with the extent of skin lesions.

The Infectious Disease Society of America has published guidelines for the treatment of IA. In accordance with these recommendations, voriconazole was the main antifungal agent used for first-line treatment in our study. Surgery is recommended for unique lesions of IA, but all of our patients presenting PCIA showed excellent 3-month prognosis, with surgical debridement performed in only 2.

In conclusion, our series of IA, although retrospective, is unique because it was extracted from a large prospective, exhaustive, and multicenter collection of IA cases. Primary cutaneous IA should be recognized early because the mycological features, management, and prognosis differ from those for SCIA, for which prognosis remains poor and is related to vascular invasion mostly in lungs and brain. In addition, the presence of any suppurative, necrotic, papulonodular, or infiltrated skin lesion in an immunocompromised patient should lead to immediate biopsy for histologic analysis and mycological skin direct examination and culture, to early diagnose a potential IA.

**ACKNOWLEDGMENTS**

The authors would especially thank all microbiologists and clinicians from the French Mycosis Study Group who actively participated in the SAIF Network and the members of the CNRMA Institut Pasteur, Paris, France.
REFERENCES

1. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–1821.

2. Parody R, Martino R, Sánchez F, et al. Predicting survival in adults with invasive aspergillosis during therapy for hematological malignancies or after hematopoietic stem cell transplantation: single-center analysis and validation of the Seattle, French, and Strasbourg prognostic indexes. Am J Hematol. 2009;84:571–578.

3. Baddley JW, Andes DR, Marr KA, et al. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis. 2010;50:1559–1567.

4. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980–1997. Clin Infect Dis. 2001;33:641–647.

5. Lorhnotary O, Gangeux JP, Sirbon K, et al., French Mycosis Study Group. Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005–2007). Clin Microbiol Infect. 2011;17:1882–1889.

6. Caillot D, Mannone L, Cuisenier B, et al. Role of early diagnosis and aggressive surgery in the management of invasive pulmonary aspergillosis in neutropenic patients. Clin Microbiol Infect. 2001;7:54–61.

7. Segal BH. Aspergillosis. N Engl J Med. 2009;360:1870–1884.

8. Van Burik JA, Colven R, Spach DH. Cutaneous aspergillosis. J Clin Microbiol. 1998;36:3115–3121.

9. Kim CW, Seo JS, Kim M-K, et al. Secondary cutaneous aspergillosis disseminated from the lungs of a patient with asthma on 1 month steroid treatment. Diagn Microbiol Infect Dis. 2010;66:104–107.

10. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic aspergillosis in patients with haematological malignancies. Eur J Clin Microbiol Infect. 2000;19:362–365.

11. D’Antonio D, Pagano L, Girmenia C, et al. Cutaneous aspergillosis in patients with haematological malignancies. Br J Dermatol. 2000;142:924–926.

12. Chakrabarti A, Gupta V, Biswas G, et al. Primary cutaneous aspergillosis: our experience in 10 years. J Infect. 1998;37:24–27.

13. Galimberti R, Kowalczuk A, Hidalgo Parra I, et al. Cutaneous aspergillosis: a report of six cases. Br J Dermatol. 1998;139:522–526.

14. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. 13 Aspergillus study group. Medicine (Baltimore). 2000;79:250–260.

15. Chakrabarti A, Gupta V, Biswas G, et al. Primary cutaneous aspergillosis: case report and review of the literature. J Am Acad Dermatol. 2009;60:594–596.

16. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. 13 Aspergillus study group. Medicine (Baltimore). 2000;79:250–260.

17. Papouli M, Rolides E, Bibishi E, et al. Primary cutaneous aspergillosis in neonates: case report and review. Clin Infect Dis. 1996;22:1102–1104.

18. Larkin JA, Greene JS, Sandin RL, et al. Primary cutaneous aspergillosis: case report and review of the literature. Infect Control Hosp Epidemiol. 1996;17:365–366.

19. Ozcan D, Gilcic AT, Haberal M. Multiple subcutaneous nodules leading to the diagnosis of pulmonary aspergillosis in a renal transplant recipient. Clin Transplant. 2008;22:120–123.

20. Colmenero I, Alonso-Sanz M, Casco F, et al. Cutaneous aspergillosis mimicking pancreatic and gouty panniculitis. J Am Acad Dermatol. 2012;67:789–791.

21. Etienne KA, Subudhi CPK, Chadwick PR, et al. Investigation of a cluster of cutaneous aspergillosis in a neonatal intensive care unit. J Hosp Infect. 2011;79:344–348.

22. Abbasi S, Shenepl J, Hughes WT, et al. Aspergillosis in children with cancer: a 34-year experience. Clin Infect Dis. 1999;29:1210–1219.

23. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: a review of 2,121 published cases. Rev Infect Dis. 1990;12:1147–1201.

24. Pasqualotto AC. Differences in pathogenicity and clinical syndromes due to Aspergillus fumigatus and Aspergillus flavus. Med Mycol. 2009;47(Suppl 1):S261–S270.

25. Yagi HI, Gumaa SA, Shamo AI, et al. Nasosinus aspergillosis in Sudanese patients: clinical features, pathology, diagnosis, and treatment. J Otolaryngol. 1999;28:90–94.

26. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327–360.